Baidu
map

Lancet:转移胰腺导管腺癌患者,Nanoliposomal irinotecan联合氟尿嘧啶和叶酸一起服用效果如何?

2015-11-23 QQduhq 译 MedSci原创

通过对既往使用吉西他滨药物治疗的转移胰腺导管腺癌患者进行的Nanoliposomal irinotecan2期实验中,研究人员发现,患者的病情有所缓解。该实验的目的在于评估在3期临床试验中,Nanoliposomal irinotecan药物单独使用或结合氟尿嘧啶和叶酸的效果。

背景:
通过对既往使用吉西他滨药物治疗的转移胰腺导管腺癌患者进行的Nanoliposomal irinotecan 2期实验中,研究人员发现,患者的病情有所缓解。该实验的目的在于评估在3期临床试验中,Nanoliposomal irinotecan药物单独使用或结合氟尿嘧啶和叶酸的效果。 


方式:
研究人员在14个国家共76家医院共417名患者进行了一个全球性、随机、非盲的3期试验。转移性胰腺导管腺癌患者(既往使用吉西他滨药物治疗)被随机分配到3组,第1组患者(共151人)接受nanoliposomal irinotecan单一治疗,剂量为120 mg/m2/每3周(相当于伊立替康100 mg/m2),第2组患者(共149人)服用氟尿嘧啶和叶酸;第3组患者(共117人)服用 nanoliposomal irinotecan(80mg/m2,相当于70 mg/m2的伊立替康单独使用)、氟尿嘧啶和叶酸(每2周添加一次)。依据病人最初的白蛋白浓度、卡氏评分和种族等随机分层讨论。直到患者疾病出现进展或难以忍受药物毒性作用时试验结束。关注的主要目标是患者整体生存率。此外,研究人员对患者的用药过程进行了缜密的评估和讨论,并评估他们使用药物的安全性。 

结果:
通过对313位患者进行分析,结果表明,第3组和第2组患者的总体生存期限分别为6.1个月(95%CI:4.8-8.9)和4.2个月(3.3-5.3,危险比0.67,95%CI:0.49-0.92;p=0.012)。第1组和第二组的中值总体生存率分别为分别为4.9个月(4.2–5.6)和4.2个月(3.6-4.9),风险比为0.99,95%CI:0.77–1.28;P=0.94,显著没有差异。一共117名患者出现3或4级不良事件,第3组患者出现药物副作用的表现及人数分别为嗜中性白血球减少症32人(27%)、腹泻15人(13%)、呕吐13人(11)、疲劳16人(14%)。 

结论:
对既往使用吉西他滨药物治疗的转移胰腺导管腺癌患者而言,Nanoliposomal irinotecan联合氟尿嘧啶和叶酸一起使用具有一定的安全性和治疗效果,不失为一种新的治疗方案。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=118939, encodeId=5e191189392a, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:26:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=118937, encodeId=ade611893e92, content=新治疗,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:24:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828318, encodeId=4729182831838, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 08 08:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652144, encodeId=be6116521441a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 04 18:08:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510816, encodeId=87951510816a4, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542845, encodeId=ec5b154284536, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2016-09-10 医路开来

    学习啦,,,

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=118939, encodeId=5e191189392a, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:26:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=118937, encodeId=ade611893e92, content=新治疗,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:24:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828318, encodeId=4729182831838, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 08 08:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652144, encodeId=be6116521441a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 04 18:08:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510816, encodeId=87951510816a4, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542845, encodeId=ec5b154284536, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2016-09-10 医路开来

    新治疗,,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=118939, encodeId=5e191189392a, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:26:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=118937, encodeId=ade611893e92, content=新治疗,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:24:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828318, encodeId=4729182831838, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 08 08:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652144, encodeId=be6116521441a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 04 18:08:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510816, encodeId=87951510816a4, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542845, encodeId=ec5b154284536, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2016-04-08 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=118939, encodeId=5e191189392a, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:26:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=118937, encodeId=ade611893e92, content=新治疗,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:24:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828318, encodeId=4729182831838, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 08 08:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652144, encodeId=be6116521441a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 04 18:08:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510816, encodeId=87951510816a4, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542845, encodeId=ec5b154284536, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2015-12-04 shock_melon
  5. [GetPortalCommentsPageByObjectIdResponse(id=118939, encodeId=5e191189392a, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:26:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=118937, encodeId=ade611893e92, content=新治疗,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:24:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828318, encodeId=4729182831838, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 08 08:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652144, encodeId=be6116521441a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 04 18:08:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510816, encodeId=87951510816a4, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542845, encodeId=ec5b154284536, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]
    2015-11-24 dzx0922892
  6. [GetPortalCommentsPageByObjectIdResponse(id=118939, encodeId=5e191189392a, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:26:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=118937, encodeId=ade611893e92, content=新治疗,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Sat Sep 10 11:24:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828318, encodeId=4729182831838, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Apr 08 08:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652144, encodeId=be6116521441a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 04 18:08:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510816, encodeId=87951510816a4, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542845, encodeId=ec5b154284536, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Nov 24 23:08:00 CST 2015, time=2015-11-24, status=1, ipAttribution=)]

相关资讯

FDA批准Regorafenib治疗转移性结直肠癌

  Regorafenib是一种口服多激酶抑制剂,9月27日,美国食品与药物管理局(FDA)宣布,已批准将其用于治疗转移性结直肠癌。批准的适应证为治疗转移性结直肠癌患者,“这些患者之前已接受氟嘧啶、奥沙利铂和伊立替康为基础的化疗、1种抗VEGF治疗,此外,如为KRAS野生型,已接受1种抗EGFR治疗。”   经由FDA针对重大治疗进展或无充分治疗疾病的新药的审查程序,Regorafenib在生产

Ⅳ期结直肠癌原发肿瘤切除术或过度使用

美国M.D.安德森癌症研究中心的一项回顾性队列研究表明,尽管大多数Ⅳ期结直肠癌">结直肠癌患者均接受原发肿瘤切除术,但从2001年开始,原发肿瘤切除手术呈现逐渐递减趋势。虽然原发肿瘤切除比率下降了,但患者存活却较以往有所改善,提示原发肿瘤切除术对于患Ⅳ期结直肠癌患者的治疗可能不是常规必要的。论文1月14日在线发表于《美国医学会 外科学》(JAMA Surg)杂志。 该研究旨在评估原发肿瘤切

Lancet Oncology:氟尿嘧啶+奥沙利铂综合疗法或提高晚期直肠癌完全缓解率

  一项来自德国直肠癌研究小组的最新研究指出,在改良了的基于氟尿嘧啶(5-Fu)的综合疗法中加入奥沙利铂(OX)是可行的,并且,与标准治疗方法相比,这种方法可使更多患者达到完全病理缓解。然而,还需更长时间的随访以便评估患者的无病生存率。该论文于2012年7月发表于《柳叶刀·肿瘤》(The Lancet Oncology)杂志。   术前放化疗、全直肠系膜切除术和应用氟尿嘧啶行

JCO:II至III期直肠癌患者的化疗新方案

  研究要点 本研究对有选择的放化疗,结合术前FOLFOX/贝伐单抗灌注方案进行了评价;32例研究参试者均取得R0切除结局;该结果表明,对于经筛选后的临床II期至III期直肠癌患者,新辅助化疗及选择性放疗似乎并不会损害患者结局。 参试患者无病生存与总生存结局   尽管临床II至III期直肠癌患者通过新辅助放化疗手段可取得较低的局部复发率,但却会

Lancet:氟尿嘧啶与提高乳腺癌无病存活率无关

氨茴环霉素和紫杉烷相结合的化疗方案可以改善早期乳腺癌的结果。最广泛地与紫杉烷相结合的药物有阿霉素和环磷酰胺(AC),或者表阿霉素和环磷酰胺(EC),或者氟尿嘧啶、阿霉素和环磷酰胺(FAC),或者氟尿嘧啶、表阿霉素和环磷酰胺(FEC)。氟尿嘧啶对AC或者EC治疗处方的贡献尚不明确。多个随机试验曾尝试评估剂量密度化疗在早期乳腺癌治疗中的作用。但鲜有试验是进行了合适的研究设计。因此,剂量密度辅助化疗

Baidu
map
Baidu
map
Baidu
map